Next Phase Newsletter

A venture capital firm based in Seattle, Washington is looking to make another 10 investments with its current fund. The fund primarily invests in Series A, but is open to Seed and Series B. The typical check size is between $250K – $2M, dependent on the stage of investment. The firm identifies themselves as very involved investors and will not invest until they see a clear path through which they can add value to the company. The firm has a strong diversity lens and looks for diverse teams including women and individuals of different backgrounds. The firm invests in USA based companies. 

 
The firm will invest in therapeutics, diagnostics, medical devices, and digital health. The fund is particularly interested in companies targeting health related issues impacting underserved populations and geographies, such as diabetes, cancer, femtech, and cardiovascular health. The fund looks for therapeutics companies to be within 6 months of submission for phase 1 trials. The fund will look at medical device companies within 6 months of 510(k) approval. The fund also requires that there is an MVP and customer attraction but does not require there to be revenue. Similarly with diagnostics, the firm requires an MVP but does not require revenue. The fund does require digital health companies to have revenue. 
 
The firm prefers to work with management teams with prior experience with startups or within the industry, but is not a firm requirement. The firm will lead or co-invest. The firm requires a board seat when leading rounds. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A firm based in Europe raised a second fund with €60M under management for Pre-Seed, Seed, and Series A investments. The fund is backed by a majority of private investors with the support of a number of institutional investors such as European Investment Fund (EIF). The firm invests €1-2M as a seed investment in the form of equity or convertible notes to help companies advance into preclinical proof of concept and can continue investing up to €6M. If additional funds are needed, the firm seeks co-investments from the strong network of investors they have in Europe. The firm is looking for investments across Europe. 
 
The firm invests in the biotech sector, exclusively in the drug development space, and with a preference for Advanced Therapies and Synthetic Biology. The firm has an interest in cutting edge technology, and it specializes in tech transfer opportunities. The firm is agnostic indication-wise and will invest in projects in preclinical stage that have reached an in vivo proof of concept in an animal model relevant for the disease for which the therapy is being developed. 
 
The firm looks for companies with a scientific founder, and preferably a C-Level executive with a track record in biotech or pharmaceutical companies. The firm prefers to lead or co-lead in Seed stage therapeutics companies and will seek a board seat. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

An investment firm headquarters in China with offices in the US focuses on early-stage investments in life science and healthcare sectors. The firm typically engages in pre-A to series B financing rounds, with initial investment sizes ranges from $500k to $8M, and potential for follow-on investments. The firm looks for opportunities mostly in Europe, and in the US and UK as well. The firm is open to both leading and co-investing. 
 
The firm is interested in therapeutics, medical devices and diagnostics. The firm is open to looking at digital health, AI -related companies but has not invested in one yet. The firm is opportunistic in terms of subsectors and indications. Some areas of interest include immunology, immuno-oncology, CNS disorders and kidney-related diseases. For therapeutics, the firm is open to looking at companies from phase I to beyond, particularly those with proof of concepts or clinical data validating their technologies. For medical devices and diagnostics, the firm tends to look for more mature companies, with product or prototype ready and as well as plans for regulatory approvals. 
 
The firm does not have specific requirements for a company’s management team but prefers to work with founding teams that have entrepreneurial experiences previously. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

The firm is a Private Equity firm that was founded in 2001 and based in Paris, France. The firm controls €550 million in assets under management across institutional and retail funds. The firm typically makes equity investments ranging from €1 to €20 million over the lifetime of the investment and is also highly interested in the in-licensing of early stage assets and technologies. The firm has an 8 year period to exit and plans to make 2-3 investments over the next 6-9 months. The firm invests in companies located throughout Europe with a focus on France.  For in-licensing opportunities the firm is willing to look globally. 
 
The firm Is currently most interested in companies developing Therapeutics and Medical Devices and is also considering investments in Diagnostics. In the Therapeutics space the firm is open in terms of indication but has strong interest in immunotherapy, vaccines, and biologics subsectors though they are also open to small molecules. In the medical device space the firm has a strong preference for investing in cardiovascular devices but considers other opportunities as well. The firm looks to invest in very early stages of company development generally when lead assets are preclinical and technologies are still in development. 
 
The firm looks to make seed investments as well as being involved in the formulation of a company. The firm is not likely to invest in companies that have already received significant institutional financing and looks to lead investments rounds. The firm also participates in spin-offs from larger companies that are looking to sell non-strategic assets.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A single family office is an active investor in early-stage companies. The firm is very flexible in terms of investment size they are generally looking to invest a minimum of $.5 million per round, depending upon size of round and estimated capital call. The firm prefers A round and later stage companies. Pre-A interest depends upon technology stage. Currently, the firm is investing only in companies based in North America. 
 
The firm is looking for breakthrough technologies with a strong social ethos in the Therapeutics, Medical Devices, and Diagnostics Sectors that address underserved medical needs or provide innovative and disruptive approaches to common medical procedures and treatments. Currently, of particular interest are optical or sound-based technologies, devices that supplant drug use, orthopedics, gene/nucleic acid-based therapies, immuno-oncology and therapies correcting or treating  loss of senses. 
 
The firm is currently reviewing co-investment opportunities in private companies and on an opportunistic basis, considering investment in micro-and small-cap public companies as a direct investor. The firm is looking for companies that have already raised seed financing and have received allowance of claims by the USPTO. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A venture capital firm headquartered in China currently holds ¥3B in assets under management. Historically, the firm focused on investing only in China. However, the current fund of $300M USD is focused on opportunities in the United States. The firm invests in early-stage life science ventures from Seed to Series B. Typical initial size of investment ranges from $100k-5M USD. 
 
The firm will consider cost-effective therapeutics and diagnostics that reach urgent and unmet clinical needs. Within therapeutics, the firm is interested in cell & gene therapy, gene editing, and organoids, and looks at pre-clinical to Phase III. Within diagnostics, the firm is open to all types of technologies and phases of development. 

With an overarching focus on the aging population, the firm is interested in technologies that can improve the quality and longevity of life. The main indication areas of interest are neurological pathways, CNS, and chronic and acute pain management. 
 
The firm does not have any requirements of the management team. Further down the road, the firm is able to support companies that are interested in entering the China market. However, having a China angle is not necessary for investment. The firm intends to act as a co-investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A venture capital firm based in Europe with offices in the US traditionally invests in agtech but is also currently interested in the intersections between bioeconomy and traditional life sciences. The firm is currently investing out of its $400M fund in Seed to Series B companies with typical check sizes ranging from $1-15M USD. The firm is opportunistic in geography but has preference in the EU and US. The firm can act as a lead investor or syndicate. 
 
In terms of life sciences, the firm is interested in R&D enabling software, non-software enabling technologies, and medical foods whether that is asset- or software-oriented. 
 
The firm does not require to take a board seat and does not have specific management team requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.